General
Preferred name
EZOGABINE
Synonyms
RETIGABINE HYDROCHLORIDE ()
retigabine ()
N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid|D-23129 ()
Retigabine dihydrochloride ()
Retigabine 2HCl ()
N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid (2HCl), D-23129 2HCl ()
D-23129, N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid ()
AWD21-360 ()
D-23129 ()
GKE-841 ()
WAY-143841 ()
Xen496 ()
Retigabine ()
Retigabina ()
Trobalt ()
Potiga ()
GW-582892X ()
XEN-496 ()
GW582892X ()
AWD-21360 ()
Retigabine ()
Retigabine (hydrochloride) ()
P&D ID
PD009342
CAS
150812-12-7
150812-13-8
Tags
available
drug
Approved by
EMA
FDA
First approval
2011
Drug indication
Epilepsy
Behcet disease
Drug Status
approved
withdrawn
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Retigabine was approved as a first in class antiepileptic drug that activates selected voltage-gated potassium channels in the brain (i.e. Kv7 family, or KCNQ, channels) .
(GtoPdb)
DESCRIPTION
Retigabine is unique among antiepileptic drugs in that it functions by activating selected voltage-gated potassium channels in the brain (i.e. Kv7 family channels) .
ABSORPTION
Rapidly absorbed and distributed, with an absolute oral bioavailability of 60%. Pharmacokinetics of ezogabine suggest first-order kinetics. ; Tmax, single oral dose = 30-120 minutes; ; Time to steady state = 3 days
TOXICITY
Lethal Dose, acute, oral, rat = 100 mg/kg;; Lethal Dose, chronic, oral, rat = 5.1 mg/kg/day, 90-day;; Most common adverse effects that lead to discontinuation of therapy include dizziness and somnolence.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
1
Compound Sets
22
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
104
Molecular Weight
303.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
3.59
TPSA
76.38
Fraction CSP3
0.19
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
KCNQ channel opener
Potassium Channel
Therapeutic Class
Anticonvulsants
Source data

